Global Targeted RNA Sequencing Sales Market Report 2023
SKU ID : QYR-22289654 | Publishing Date : 02-Jan-2023 | No. of pages : 105
Market Analysis and Insights: Global Targeted RNA Sequencing Market
Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest and offers both quantitative and qualitative information. Targeted RNA-Seq can be achieved via either enrichment or amplicon-based approaches, both of which enable gene expression analysis in a focused set of genes of interest, with enrichment assays also providing the ability to detect both known and novel gene fusion partners in many sample types.
In the report, we only collect information about the companies who can provide targeted RNA sequencing service.
Due to the COVID-19 pandemic, the global Targeted RNA Sequencing market size is estimated to be worth US$ 1800.6 million in 2022 and is forecast to a readjusted size of US$ 7570 million by 2029 with a CAGR of 22.5% during the forecast period 2023-2029. Fully considering the economic change by this health crisis, Exome Sequencing accounting for % of the Targeted RNA Sequencing global market in 2022, is projected to value US$ million by 2029, growing at a revised % CAGR from 2023 to 2029. While Research Institutes segment is altered to an % CAGR throughout this forecast period.
Market competition is not intense. Thermo Fisher, Illumina, Roche Holdings, BGI, Eurofins, etc. are the leaders of the industry, with about 52% market shares.
North America is the largest consumption place, with a consumption market share nearly 32%. Following North America, Europe is the second largest consumption place with the consumption market share of 28%.
Global Targeted RNA Sequencing Scope and Market Size
The global Targeted RNA Sequencing market is segmented by company, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Targeted RNA Sequencing market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2018-2029.
Segment by Type
Exome Sequencing
Enrichment Sequencing
Amplicon Sequencing
Segment by Application
Research Institutes
Hospitals & Clinics
Biotechnology Company
Diagnostic Lab
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Thermo Fisher
Illumina
Roche Holdings
BGI
Eurofins
LabCorp
Berry Genomics
Macrogen
GENEWIZ
Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest and offers both quantitative and qualitative information. Targeted RNA-Seq can be achieved via either enrichment or amplicon-based approaches, both of which enable gene expression analysis in a focused set of genes of interest, with enrichment assays also providing the ability to detect both known and novel gene fusion partners in many sample types.
In the report, we only collect information about the companies who can provide targeted RNA sequencing service.
Due to the COVID-19 pandemic, the global Targeted RNA Sequencing market size is estimated to be worth US$ 1800.6 million in 2022 and is forecast to a readjusted size of US$ 7570 million by 2029 with a CAGR of 22.5% during the forecast period 2023-2029. Fully considering the economic change by this health crisis, Exome Sequencing accounting for % of the Targeted RNA Sequencing global market in 2022, is projected to value US$ million by 2029, growing at a revised % CAGR from 2023 to 2029. While Research Institutes segment is altered to an % CAGR throughout this forecast period.
Market competition is not intense. Thermo Fisher, Illumina, Roche Holdings, BGI, Eurofins, etc. are the leaders of the industry, with about 52% market shares.
North America is the largest consumption place, with a consumption market share nearly 32%. Following North America, Europe is the second largest consumption place with the consumption market share of 28%.
Global Targeted RNA Sequencing Scope and Market Size
The global Targeted RNA Sequencing market is segmented by company, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Targeted RNA Sequencing market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2018-2029.
Segment by Type
Exome Sequencing
Enrichment Sequencing
Amplicon Sequencing
Segment by Application
Research Institutes
Hospitals & Clinics
Biotechnology Company
Diagnostic Lab
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Thermo Fisher
Illumina
Roche Holdings
BGI
Eurofins
LabCorp
Berry Genomics
Macrogen
GENEWIZ
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.